5 55.4–110.6 15 73.2 41.0–120.7 6 42.9* 28.1–62.9 4 70.8 19.3–181.2 Respiratory disease 13 142.4 75.8–243.5 3 69.7 14.4–203.8 4 34.4* 9.4–88.0 0 0 0–235.3 Other causes 9 49.8* 22.7–94.5 6 68.9 25.3–149.9 20 73.8 45.1–114.0 0 0 0–128.3 Unknown 4     0     4     1     Neoplasm, cause specific 28     11     41     2      Oesophagus

find protocol 0 0 0–434.8 0 0 0–801.0 4 301.2 82.1–771.2 0 0 0–3,088.4  Stomach and small intestine 2 69.3 8.4–250.3 2 161.6 19.6–583.6 3 81.4 16.8–237.9 1 303.0 7.7–1,688.4  Large intestine 1 46.8 1.2–260.5 2 181.5 22.0–655.5 4 111.1 30.3–248.4 0 0 0–988.7  Rectum 2 213.5 25.9–771.0 0 0 0–701.6 4 317.7 86.6–813.5 0 0 0–2,651.1  Liver and biliary passages 1 181.2 4.6–1,009.4 1 354.6 9.0–1,975.8 2 217.9 26.4–787.0 0 0 0–4,048.3  Pancreas 2 148.7 18.0–537.2 0 0 0–429.8 1 44.6 1.1–248.5 0 0 0–1,673.6  Trachea and lung cancer 13 107.0 57.0–183.0 4 62.0 19.9–158.9 9 43.4* 19.8–82.3 0 0 0–181.5  Skin 0 0 0–1,089.4 0 0 0–2,024.1 3 575.8* 118.8–1,682.8 0 0 0–8,096.6  Kidney 1 127.7 3.2–711.6 0 0 0–690.3 1 65.9 1.7–367.3 0 0 0–2,674.8  Prostate cancer 2 67.1 8.1–242.4 0 0 0–208.8 3 75.2 15.5–219.8 0 0 0–696.7  Bladder cancer 3 252.3 52.0–737.4 0 0 0–513.0 0 0 0–169.3 0 0 0–1,849.2  Brain 0 0 0–649.8 0 0 0–1,105.4 1 99.5 2.5–554.4 0 0 0–4,608.8  Other lymphoma 0 0 0–606.4 STA-9090 0 0 0–963.3

1 90.8 2.3–506.1 0 0 0–3,609.3  Multiple myeloma 0 0 0–367.4 0 0 0–1,232.8 1 129.0 3.3–718.9 1 1,538.5 39.0–8,571  Leukaemia 0 0 0–374.0 1 249.4 6.3–1,389.4 2 155.5 18.8–561.8 0 0 0–2,826.1  Unspecified 1 75.6 1.9–422.1 1 151.8 3.8–845.7 2 98.9 12.0–357.3 0 0 0–1,751.9 * P value <0.05 Discussion After 52 years of follow up, this cohort of 570 workers exposed to dieldrin and aldrin does not demonstrate any excess cancer mortality risk that could be related to exposure. There were no additional cases since the previous update (Swaen

et Adenosine al. None of the other epidemiological or animal studies Epigenetics Compound Library cell line available report a similar finding.